ClinicalTrials.gg
CompletedNCT02781584Updated Mar 16, 2022Results posted

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of SEL and FIR in Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD), sponsored by Gilead Sciences. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
7th of 16
220 · median 161
Started
2016
with 5 others
Phase 2
11 of 16
none open now
Registered
6th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 7th largest by enrollment, is one of 6 that started in 2016, is one of 11 in phase 2, and was the 6th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
  • Nonalcoholic Fatty Liver Disease (NAFLD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females between 18-75 years of age (Cohorts 1-9: 18-75 years and Cohorts 10-13: ≥ 18 years); inclusive based on the date of the screening visit
  • Willing and able to provide prior to any study specific procedures being performed
  • For Cohorts 1 through 6 and 9, individuals must meet the following conditions:

    • Clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)
    • Screening FibroTest® \< 0.75, unless a historical liver within 12 months of Screening does not reveal cirrhosis. In individuals with Gilbert's syndrome or hemolysis, FibroTest® will be calculated using direct instead of total bilirubin,
    • Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 10% steatosis,
    • Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.88 kPa, OR
    • A historical liver biopsy within 12 months of Screening consistent with NASH (defined as the presence of steatosis, inflammation, and ballooning) with stage 2-3 fibrosis according to the NASH Clinical Research Network (CRN) classification (or equivalent), AND
    • No documented weight loss > 5% between the date of the liver biopsy and Screening;
  • For Cohorts 7 and 8, individuals must have a clinical diagnosis of NAFLD and have at least one of the following criteria:

    • Screening MRE with liver stiffness ≥ 4.67 kPa,
    • A historical FibroScan® ≥ 14 kPa within 6 months of Screening,
    • Screening FibroTest® ≥ 0.75,
    • A historical liver biopsy consistent with stage 4 fibrosis according to the NASH CRN classification (or equivalent);
  • For Cohorts 10 and 11, individuals must have a clinical diagnosis of NAFLD and meet at least two criteria for metabolic syndrome modified from the NCEP ATP III Guidelines and one of the following criteria at Screening:

    • A historical liver biopsy within 6 months of Screening consistent with NASH and bridging fibrosis (F3) or within 12 months of Screening consistent with NASH and compensated cirrhosis (F4) in the opinion of the investigator,
    • Screening liver stiffness by MRE ≥ 3.64 kPa;
    • Screening liver stiffness by FibroScan® ≥ 9.9 kPa;
  • For Cohorts 12 and 13, individuals must have a clinical diagnosis of NAFLD/NASH and at least two criteria for metabolic syndrome as modified from the NCEPT ATP III Guidelines, OR one of the following criteria:

    • A historical liver biopsy within 6 months of Screening consistent with NASH for individuals without compensated cirrhosis (F4); or within 12 months of Screening consistent with NASH for individuals with compensated cirrhosis (F4) in the opinion of the investigator,
    • A historical MRE with liver stiffness ≥ 2.88 kPa within 6 months of Screening,
    • A historical FibroScan® with liver stiffness ≥ 9.9 kPa within 6 months of Screening, AND
    • No documented weight loss > 5% between the date of the historical liver biopsy, historical MRE, or historical FibroScan® and Screening;
  • count ≥ 100,000/µL;
  • Serum creatinine \< 2 mg/dL (Cohorts 1-9) at Screening;
  • Estimated (eGFR) ≥ 80 mL/min (Cohorts 10-11) or ≥ 60 mL/min (Cohorts 12-13), as calculated by the equation at Screening;
  • For Cohorts 10-13, serum triglyceride level ≥ 150 mg/dL at Screening.

Key Exclusion Criteria:

  • Pregnant or lactating females
  • Other causes of liver disease including , viral, and alcoholic liver disease
  • Any history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
  • For Cohorts 7-8, 10-13, -Turcotte (CPT) score > 6
  • History of liver transplantation
  • History of hepatocellular carcinoma;
  • Weight reduction surgery in the past 2 years or planned during the study;
  • Documented weight loss > 5% between the date of the historical liver biopsy and Screening, if applicable;
  • (BMI) \< 18 kg/m2;
  • > 5 x at Screening;
  • For Cohorts 10-13, ≥ 9.5% (or serum fructosamine ≥ 381 µmol if HbA1c is unable to be resulted) at Screening;
  • For Cohorts 10-13, ≤ 10.6 g/dL at Screening;
  • > 1.2 (Cohorts 1-9) or INR > 1.4 (Cohorts 10-13) at Screening, unless on anticoagulation therapy;
  • Total bilirubin > 1x ULN (Cohorts 1 through 6 and 9), >1.5 x ULN (Cohorts 7 and 8), or >1.3 x ULN (Cohorts 10-13) except in confirmed cases of Gilbert's syndrome;
  • Triglycerides ≥ 500 mg/dL (Cohorts 5-8 and 10-13) or ≥ 250 mg/dL (Cohort 9) at Screening;
  • Model for End-Stage Liver Disease (MELD) score > 12 at Screening (Cohorts 10 -13), unless due to an alternate etiology such as therapeutic anticoagulation;
  • Chronic (HBsAg positive);
  • Chronic (HCV RNA positive). individuals cured of HCV infection less than 2 years prior to the Screening visit are not eligible (Cohorts 10-13);
  • Ab positive;
  • Presence of gallstones within 6 months of Screening (Cohorts 10-13);
  • Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females (1oz/30 mL of alcohol is present in 1 12oz/360 mL beer, 1 4oz/120 mL glass of wine, and a 1 oz/30 mL measure of 40% proof alcohol);
  • Positive urine screen for amphetamines, cocaine or opiates (i.e., heroin, morphine) at Screening. Individuals on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to Screening may be included in the study. Individuals with a positive urine drug screen due to prescription opioid-based medication are eligible if the prescription and diagnosis are reviewed and approved by the investigator;
  • Unstable cardiovascular disease;
  • History of intestinal resection of the extent that would result in malabsorption;
  • Use of any prohibited concomitant medications as described in the protocol;
  • History of a within 5 years of Screening with the following exceptions:

    • Adequately treated carcinoma in situ of the cervix,
    • Adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Cohort 1: SEL 18 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.

    Drug: SEL

  • Experimental
    Cohort 2: FIR 20 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.

    Drug: FIR

  • Experimental
    Cohort 3: CILO 30 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.

    Drug: CILO

  • Experimental
    Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.

    Drug: SEL · Drug: CILO

  • Experimental
    Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.

    Drug: SEL · Drug: FIR

  • Experimental
    Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.

    Drug: FIR · Drug: CILO

  • Experimental
    Cohort 7: CILO 20 mg (Cirrhotic)

    Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.

    Drug: FIR

  • Experimental
    Cohort 8: CILO 30 mg (Cirrhotic)

    Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.

    Drug: CILO

  • Experimental
    Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)

    Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.

    Drug: SEL · Drug: FIR · Drug: CILO

  • Experimental
    Cohort 10: FIR 20 mg + FENO 48 mg

    Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.

    Drug: FIR · Drug: FENO

  • Experimental
    Cohort 11: FIR 20 mg + FENO 145 mg

    Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.

    Drug: FIR · Drug: FENO

  • Experimental
    Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g

    Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.

    Drug: FIR · Drug: CILO · Drug: VAS

  • Experimental
    Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg

    Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.

    Drug: FIR · Drug: CILO · Drug: FENO

Interventions

  • DrugSEL

    Administered orally once daily

    Also known as: GS-4997

  • DrugFIR

    Administered orally once daily

    Also known as: GS-0976

  • DrugCILO

    Administered orally once daily

    Also known as: GS-9674

  • DrugFENO

    Administered orally once daily

  • DrugVAS

    Administered orally two times daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events

    Treatment-emergent AEs were defined as events that met 1 or both of the following criteria: * Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug

    Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.

  2. Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events

    A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following: * Death * Life-threatening * In-patient hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * A congenital anomaly/birth defect * A medically important event or reaction

    Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.

  3. Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13.

    Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.

07

Results

Posted Feb 2, 2022

Participant flow

Participants were enrolled in study sites in the United States and New Zealand. The first participant was screened on 13 June 2016. The last study visit occurred on 17 December 2020.

Pre-treatment Phase
Participant flow — Pre-treatment Phase
MilestoneCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Started00000000015163333
Completed00000000015163032
Not completed0000000000031
Withdrew: Investigator's discretion0000000000021
Withdrew: Adverse event0000000000010
Treatment Phase
Participant flow — Treatment Phase
MilestoneCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Started10101020202010101315163032
Completed1010102020191091315152832
Not completed0000010100120
Withdrew: Withdrew consent0000010000120
Withdrew: Adverse event0000000100000

Outcome measures

PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events

Treatment-emergent AEs were defined as events that met 1 or both of the following criteria: * Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug

Time frame:
Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
percentage of participantsCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events506050254050807076.9286.6787.54037.5
PrimaryPercentage of Participants Who Experienced Treatment Emergent Serious Adverse Events

A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following: * Death * Life-threatening * In-patient hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * A congenital anomaly/birth defect * A medically important event or reaction

Time frame:
Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events
percentage of participantsCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events0005551007.69003.333.12
PrimaryPercentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13.

Time frame:
Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities
percentage of participantsCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities202040102010403015.46.712.56.76.3

Adverse events

Collected over Adverse Events: First dose date up to last dose (Cohorts 1-9: up to 12 weeks; Cohorts 10-11: up to 26 weeks; Cohorts 12-13: up to 8 weeks) plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase. All-cause Mortality: Cohorts 1 through 6 and 9: Enrollment up to 12 weeks plus 30 days; Cohorts 7-8: Randomization up to 12 weeks plus 30 days; Cohorts 10-11: Randomization up to 26 weeks plus 30 days; Cohort 12-13: Randomization up to 8 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: SEL 18 mg (Non-cirrhotic)0/10 (0%)0/10 (0%)5/10 (50%)
Cohort 2: FIR 20 mg (Non-cirrhotic)0/10 (0%)0/10 (0%)6/10 (60%)
Cohort 3: CILO 30 mg (Non-cirrhotic)0/10 (0%)0/10 (0%)5/10 (50%)
Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)0/20 (0%)1/20 (5%)5/20 (25%)
Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)0/20 (0%)1/20 (5%)8/20 (40%)
Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)0/20 (0%)1/20 (5%)10/20 (50%)
Cohort 7: CILO 20 mg (Cirrhotic)0/10 (0%)1/10 (10%)8/10 (80%)
Cohort 8: CILO 30 mg (Cirrhotic)0/10 (0%)0/10 (0%)7/10 (70%)
Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)0/13 (0%)1/13 (7.7%)10/13 (76.9%)
Cohort 10: FIR 20 mg + FENO 48 mg0/15 (0%)0/15 (0%)13/15 (86.7%)
Cohort 11: FIR 20 mg + FENO 145 mg0/16 (0%)0/16 (0%)14/16 (87.5%)
Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g0/30 (0%)1/30 (3.3%)7/30 (23.3%)
Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg0/32 (0%)1/32 (3.1%)9/32 (28.1%)
Most frequent serious events
Most frequent serious events
EventCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
Small intestinal obstructionGastrointestinal disorders0/100/100/100/200/200/201/100/100/130/150/160/300/32
Pneumonia viralInfections and infestations0/100/100/100/200/200/200/100/101/130/150/160/300/32
CellulitisInfections and infestations0/100/100/101/200/200/200/100/100/130/150/160/300/32
Tooth abscessInfections and infestations0/100/100/100/201/200/200/100/100/130/150/160/300/32
Urinary tract infectionInfections and infestations0/100/100/100/200/201/200/100/100/130/150/160/300/32
Non-cardiac chest painGeneral disorders0/100/100/100/200/200/200/100/100/130/150/161/300/32
AppendicitisInfections and infestations0/100/100/100/200/200/200/100/100/130/150/160/301/32
Most frequent other events
Showing 10 of 103
Most frequent other events
EventCohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg
HeadacheNervous system disorders1/100/100/100/201/202/200/101/105/131/154/161/301/32
Upper respiratory tract infectionInfections and infestations0/100/101/100/200/202/200/100/102/135/151/160/300/32
ConstipationGastrointestinal disorders1/100/100/100/201/200/200/100/103/133/151/160/301/32
Back painMusculoskeletal and connective tissue disorders0/100/100/100/200/200/200/100/103/132/151/160/302/32
AnaemiaBlood and lymphatic system disorders0/100/100/100/200/200/202/100/100/130/150/160/301/32
Acute sinusitisInfections and infestations0/100/102/101/200/200/200/100/100/130/150/160/301/32
ArthralgiaMusculoskeletal and connective tissue disorders0/101/100/100/200/200/200/101/100/133/152/160/303/32
DizzinessNervous system disorders0/100/100/100/200/201/201/102/102/131/152/160/300/32
PruritusSkin and subcutaneous tissue disorders0/100/101/100/200/200/200/102/100/131/150/160/300/32
Pruritus generalisedSkin and subcutaneous tissue disorders0/100/100/100/200/200/200/102/100/130/150/160/300/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mgTotal
Mean54 ± 7.057 ± 9.853 ± 12.356 ± 7.848 ± 13.855 ± 10.760 ± 11.160 ± 9.556 ± 8.259 ± 9.752 ± 14.256 ± 11.152 ± 11.555 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mgTotal
Female95913111276111092422148
Male1517983425761068
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mgTotal
Hispanic or Latino898125116392101517115
Not Hispanic or Latino21281594741361515101
Unknown or Not Reported00000000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mgTotal
Asian00000200110015
Black or African American00011000000013
Native Hawaiian or Pacific Islander00001000000001
White10101019171710101214163030205
Other00001100000002
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: SEL 18 mg (Non-cirrhotic)Cohort 2: FIR 20 mg (Non-cirrhotic)Cohort 3: CILO 30 mg (Non-cirrhotic)Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)Cohort 7: CILO 20 mg (Cirrhotic)Cohort 8: CILO 30 mg (Cirrhotic)Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)Cohort 10: FIR 20 mg + FENO 48 mgCohort 11: FIR 20 mg + FENO 145 mgCohort 12: FIR 20 mg + CILO 30 mg + VAS 2gCohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mgTotal
New Zealand00003300100007
United States10101020171710101215163032209
08

Study locations

13 sites
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Altman Clinical and Translational Research Clinic
    La Jolla, California 92093, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford Hospital and Clinics (SHC)
    Stanford, California 94305, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Delta Research Partners, LLC
    Bastrop, Louisiana 71220, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • Pinnacle Clinical Research, PLLC
    Live Oak, Texas 78233, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research, PLLC
    San Antonio, Texas 78229, United States
  • Auckland Clinical Studies Ltd
    Auckland, 1010, New Zealand
09

References and documents

Publications

  • Lawitz E, Neff G, Ruane P, Ziad Y, Jia C, Chuang J, et al. Fenofibrate Mitigates Increases in Serum Triglycerides Due to the ACC Inhibitor Firsocostat in Patients with Advanced Fibrosis Due to NASH. Poster presented at: The American Association for the Study of Liver Diseases (AASLD): The Liver Meeting; November 8-12, 2019; Boston, MA.
  • Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, McHutchison JG, Subramanian GM, Myers RP, Middleton MS, Sirlin C, Loomba R, Nyangau E, Fitch M, Li K, Hellerstein M. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991.e3. doi: 10.1016/j.cgh.2018.04.042. Epub 2018 Apr 26. PubMed 29705265 ↗
  • Lawitz E, Herring R, Younes ZH, Gane E, Ruane P, Schall RA, et al. Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK1) Inhibitor (Selonsertib) in Combination With An Acetyl-CoA Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor Agonist (GS-9674) in Nash [Abstract PS-105]. European Association for the Study of the Liver (EASL); 2018 11-15 April; Paris, France.
  • Lawitz E, Li K, Tarrant JM, Vimal M, Xu R, Song Q, et al. Hepatic de Novo Lipogenesis is Elevated in Patients with NASH Independent of Disease Severity [Abstract 2217]. American Association for the Study of Liver Diseases (AASLD); 2017 20-24 October Washington, DC.
  • Lawitz EJ, Poordad F, Coste A, Loo N, Djedjos CS, McColgan B, et al. Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH [Abstract GS-009]. The International Liver Congress™ 2017: European Association for the Study of the Liver (EASL); 2017 19-23 April; Amsterdam, the Netherlands.
  • Lawitz E, Bhandari BR, Ruane P, Kohli A, Harting E, Jia C, et al. Fenofibrate is Safe and Mitigates Increases in Serum Triglycerides in NASH Patients Treated with the Combination of the ACC Inhibitor Firsocostat and the FXR Agonist Cilofexor: A Randomized Trial. Poster presented at: The European Association for the Study of the Liver (EASL): International Liver Congress; June 23-26, 2021; Virtual Meeting.
  • Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3. doi: 10.1016/j.cgh.2021.12.044. Epub 2022 Jan 6. PubMed 34999207 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Dec 2020, 54 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 54 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
May 24, 2016
StartActual
Jun 13, 2016
Primary completionActual
Dec 17, 2020
CompletionActual
Dec 17, 2020
Results first posted
Feb 2, 2022
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02781584
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 24, 2016
Start date
Jun 13, 2016
Primary completion
Dec 17, 2020
Completion
Dec 17, 2020
Results posted
Feb 2, 2022
Last update
Mar 16, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selonsertib · Firsocostat · Cilofexor

Start the discussion